LD-2 disclosure · 4th Quarter - Report
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Client
- Description
- no change
- Location
- District of Columbia · United States of America
Registrant
- Description
- Issues relating to prescription drug benefits
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
3 issuesMedicare/Medicaid
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits H.R.10545- December Continuing Resolution H.R.9096- Pharmacists Fight Back Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation
Lobbyistsmr JONATHAN M HEAFITZ · JUAN CARLOS SCOTT · JOCELYN WILES · LUCIA LEBENS · EMILY THREADGILL
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · Health & Human Services, Dept of (HHS) · Centers For Medicare and Medicaid Services (CMS)
Health Issues
Issues related to prescription drug coverage and pharmacy benefits Issues related to the prescription drug marketplace, patents, and competition Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits H.R.10545- December Continuing Resolution H.R.9096- Pharmacists Fight Back Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation
Lobbyistsmr JONATHAN M HEAFITZ · JUAN CARLOS SCOTT · JOCELYN WILES · LUCIA LEBENS · EMILY THREADGILL
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · Health & Human Services, Dept of (HHS) · Centers For Medicare and Medicaid Services (CMS)